Cephapirin

Summary

Cephapirin (CHEMBL1599) is an approved small-molecule antibacterial drug (ATC J01DB08); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DB08
• Indications: 1 condition
• Chemistry: 423.5 Da · C17H17N3O6S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1599
Name	Cephapirin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	30699
ChEBI	CHEBI:554446
ATC	J01DB08
Molecular formula	C17H17N3O6S2
Molecular weight	423.5
InChIKey	UQLLWWBDSUHNEB-CZUORRHYSA-N

SMILES: CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CSC3=CC=NC=C3)SC1)C(=O)O

IUPAC name: (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A cephalosporin with acetoxymethyl and 2(pyridin-4-ylsulfanyl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. It is used (as its sodium salt) as an antibiotic, being effective against gram-negative and gram-positive organisms.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefapirin, Cefapirina, Cefapirine, cephapirin, Cephapirin, CEFAPIRINE, CEPHAPIRIN, CEPHAPIRIN SODIUM, cefapirin

Parent form; salt/anhydrous children: CHEMBL1201043, CHEMBL3989837

Patent coverage: 2,983 distinct patent families (10,929 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Nuclear receptor subfamily 1 group I member 2.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).